Nalan Akgul Babacan
Overview
Explore the profile of Nalan Akgul Babacan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eroglu Z, Broman K, Thompson J, Nijhuis A, Hieken T, Kottschade L, et al.
J Immunother Cancer
. 2022 Aug;
10(8).
PMID: 36002183
Until recently, most patients with sentinel lymph node-positive (SLN+) melanoma underwent a completion lymph node dissection (CLND), as mandated in published trials of adjuvant systemic therapies. Following multicenter selective lymphadenectomy...
2.
Telli T, Ozturk M, Alan O, Hasanov R, Kostek O, Arikan R, et al.
Future Oncol
. 2022 Jun;
18(22):2425-2439.
PMID: 35695547
The aim of this study was to investigate quality-of-life (QoL) in breast cancer (BC) patients treated with adjuvant endocrine therapy (AET). We designed a cross-sectional study of 233 BC patients...
3.
Basoglu T, Akar K, Bagci P, Babacan N, Ozturk M, Ozturk F, et al.
Balkan Med J
. 2021 Dec;
39(1):12-20.
PMID: 34928235
Background: Pancreatic ductal adenocarcinoma differs from other solid tumors with its unique immunosuppressive microenvironment and non-immunogenic feature. There are not many studies in the literature investigating the effect of these...
4.
Yildiz F, Demirci U, Kucukarda A, Buyuksimsek M, Sakalar T, Topcu T, et al.
J Cancer Res Ther
. 2021 Dec;
17(6):1525-1529.
PMID: 34916389
Background: Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine carcinoma of the skin. In this study, we aimed to evaluate the clinicopathologic characteristics, treatment outcomes, and survival...
5.
Babacan N, Peguero E, Forsyth P, Eroglu Z
Oncologist
. 2021 Jul;
26(10):e1887-e1889.
PMID: 34227206
Introduction: BRAF inhibitors such as encorafenib and vemurafenib in combination with MEK inhibitors are commonly used for the treatment of patients with BRAF V600-mutant melanoma. Case Presentation: A patient with...
6.
Alan O, Telli T, Aktas B, Koca S, Okten I, Hasanov R, et al.
World J Surg Oncol
. 2020 Sep;
18(1):242.
PMID: 32907593
Purpose: Neoadjuvant chemotherapy is the standard front-line treatment modality in locally advanced breast cancer. Achieving pathological complete response (pCR) is a significant prognostic factor for prolonged disease-free and overall survival....
7.
Robinson L, Babacan N, Tanvetyanon T, Henderson-Jackson E, Bui M, Druta M
J Thorac Cardiovasc Surg
. 2020 Jul;
162(1):274-284.
PMID: 32711968
Objective: Primary pulmonary sarcomas (PPS) and pulmonary carcinosarcomas (PCS) are rare aggressive lung malignancies. We reviewed our 21-year experience with the surgical and nonsurgical treatment of both tumors, comparing their...
8.
Alan O, Telli T, Basoglu Tuylu T, Arikan R, Demircan N, Ercelep O, et al.
J Oncol Pharm Pract
. 2020 May;
27(2):329-339.
PMID: 32349641
Purpose: Malignant high-grade gliomas are the most common and aggressive type of primary brain tumor, and the prognosis is generally extremely poor. In this retrospective study, we analyzed the outcome...
9.
Demirelli B, Babacan N, Ercelep O, Ozturk M, Kaya S, Tanrikulu E, et al.
Nutr Cancer
. 2020 Apr;
73(2):230-238.
PMID: 32270713
Gastric carcinoma (GC) patients usually present with locally advanced or metastatic disease; therefore treatment aim is mainly palliation. In this study our purpose is to analyze the prognostic values of...
10.
Babacan N, Eroglu Z
Curr Oncol Rep
. 2020 Mar;
22(4):38.
PMID: 32198651
Purpose Of Review: While anti-PD-1 antibodies have been a breakthrough in the treatment of patients with advanced melanoma, a substantial proportion of patients are still refractory to or progress after...